People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...
GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...
Medpage Today on MSN4d
GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood ClotsPropensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather ...
Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...
Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...
In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...
Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...
Glucagon-like peptide-1 (GLP-1) receptor agonists can stop people from developing kidney complications, new research has ...
Health.com on MSN8d
Can’t Afford Ozempic, Other GLP-1 Drugs? Here’s What to Do, According to ExpertsMore than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...
Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster presentation ...
Greater weight loss was linked to greater savings, which may be directionally correct but isn’t necessarily the whole story.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback